SCHEMBL864265

SCHEMBL864265

CC(c1cc2cccc(Cl)c2nc1N)n1cnc2c(N)nc(N)nc21

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.52
CCNB1 P14635 3/20 0.52
CCNE1 P24864 3/20 0.52
CDK2 P24941 3/20 0.52
PIK3CD O00329 6/20 0.41
PDE8A O60658 3/20 0.40
PDE2A O00408 2/20 0.40
PDE4D Q08499 1/20 0.40
KCNH2 Q12809 1/20 0.40
PDE10A Q9Y233 1/20 0.40
ADORA2A P29274 1/20 0.39
SLC29A1 Q99808 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22304003 0.73 PIK3CD (0.42) PIK3CDPDE10A
SCHEMBL864009 0.72 PIK3CD (0.41) PIK3CDPDE10A
Hydrochloric Acid SCHEMBL863977 0.71 LMNA (0.49) PIK3CDPDE10A
Hydrochloric Acid SCHEMBL863976 0.71 LMNA (0.49) PIK3CDPDE10A
SCHEMBL29611365 0.70 CDK1 (1.00) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL756644 0.70 CDK1 (1.00) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL864264 0.70 PIK3CD (0.40) PIK3CD
SCHEMBL24239234 0.69 CDK1 (0.78) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL29248683 0.68 PIK3CD (0.58) CDK1CCNB1CCNE1CDK2PIK3CD
SCHEMBL28083712 0.68 CDK1 (0.76) CDK1CCNB1CCNE1CDK2PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA CDK1 120/4885CCNB1 2015/4885CCNE1 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.